CARY, N.C.--(BUSINESS WIRE)--Trana Discovery, Inc., a drug discovery technology company, today announced plans for the development of a new High-Throughput Screening (HTS) assay capable of selectively identifying compounds that inhibit the reproduction of Staphylococcus aureus bacteria through a unique mechanism of action: the target pathogen’s ability to use transfer RNA (tRNA) in replication. Final development and commercialization of the assay is made possible by a $250,000 Small Business Research Loan awarded to the company by the North Carolina Biotechnology Center. Trana will engage with several local biotechnology resources to advance the assay to HTS status, opening the way for the discovery, development, and market availability of critically needed new anti-infectives for the treatment of Staphylococcus aureus infections.
